Erythromycin in the management of troublesome BCG lesions.
We have recently seen six persons with troublesome post-BCG lesions. All lesions healed whilst on therapy with erythromycin for a period of 2-4 weeks. Erythromycin has some effect on the atypical mycobacteria ( Wolinsky et al. 1957) but its use has not previously been described for treatment of BCG lesions.
D000038:Abscess / Q000188:drug therapy* / Q000209:etiology; D000293:Adolescent; D000328:Adult; D001500:BCG Vaccine / Q000009:adverse effects*; D004917:Erythromycin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D012871:Skin Diseases / Q000188:drug therapy / Q000209:etiology; D012883:Skin Ulcer / Q000188:drug therapy* / Q000209:etiology
D001500:BCG Vaccine; D004917:Erythromycin